

# ForPatients

by Roche

Multiple Sclerosis (MS) Clinically Isolated Syndrome (CIS)

## A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab

**Trial Status**  
Recruiting

**Trial Runs In**  
4 Countries

**Trial Identifier**  
NCT04998851 2021-000063-79  
MN42989

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

### ***Trial Summary:***

This study will evaluate the pharmacokinetics of ocrelizumab in the breastmilk of lactating women with clinically isolated syndrome (CIS) or multiple sclerosis (MS) [in line with the locally approved indications] treated with ocrelizumab, by assessing the concentration of ocrelizumab in mature breastmilk, as well as the corresponding exposure and pharmacodynamic effects (blood B cell levels) in the infants.

**Hoffmann-La Roche**  
Sponsor

**Phase 4**  
Phase

---

**NCT04998851 2021-000063-79 MN42989**  
Trial Identifiers

---

### ***Eligibility Criteria:***

**Gender**  
Female

**Age**  
>=18 Years & <= 40 Years

**Healthy Volunteers**  
No

---